ArticleNeurology(R) neuroimmunology & neuroinflammation2020
Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS.
Open access · goldAbstract read
In one paragraph
Article in Neurology(R) neuroimmunology & neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- The Elusive B Cell Antigen in Multiple Sclerosis: Time to Rethink CNS B Cell Functions.International journal of molecular sciences · 2025Pooled it
- Using Synthetic Glycans to Investigate Anti-Glycan Antibodies and Explore Their Medical Potential.Angewandte Chemie (International ed. in English) · 2026Review
- Linking Nutrients to Multiple Sclerosis Pathogenesis: Biological Evidence and Clinical Implications.Nutrients · 2025Review
- The antibody repertoire of autoimmune sensory neuronopathies targets pathways of the innate and adaptive immune system. An autoantigenomic approach.Journal of translational autoimmunity · 2025Article
- Inactivation of the CMAH gene and deficiency of Neu5Gc play a role in human brain evolution.Inflammation and regeneration · 2025Review
- Serum antibody screening using glycan arrays.Chemical Society reviews · 2024Review
- A systematic review reveals conflicting evidence for the prevalence of antibodies against the sialic acid 'xenoautoantigen' Neu5Gc in humans and the need for a standardised approach to quantification.Frontiers in molecular biosciences · 2024Review
- CIDP Antibodies Target Junction Proteins and Identify Patient Subgroups: An Autoantigenomic Approach.Neurology(R) neuroimmunology & neuroinflammation · 2021Observational
- Challenging the Role of Diet-Induced Anti-Neu5Gc Antibodies in Human Pathologies.Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 5 countries.
Kayluz F BoliganFrom the Institute of Pharmacology (K.F.B., S.v.G.), University of Bern, Switzerland; Neurologic Clinic and Policlinic (J.O., L.K., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Switzerland; Department of Neurology with Institute of Translational Neurology (C.W.K., J.D.L.), University Hospital Münster, University of Münster, Germany; Laboratory of Neuroinflammation (C.W.K., B.P., J.D.L.), Institute of Experimental Immunology, University of Zurich, Switzerland; Department for BioMedical Research (DBMR) (R.R.), University of Bern, Switzerland; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Science (N.B.), Moscow, Russia; Auckland University of Technology (N.B.), New Zealand; and Department of Surgery (R.D.C.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Johanna OechteringFrom the Institute of Pharmacology (K.F.B., S.v.G.), University of Bern, Switzerland; Neurologic Clinic and Policlinic (J.O., L.K., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Switzerland; Department of Neurology with Institute of Translational Neurology (C.W.K., J.D.L.), University Hospital Münster, University of Münster, Germany; Laboratory of Neuroinflammation (C.W.K., B.P., J.D.L.), Institute of Experimental Immunology, University of Zurich, Switzerland; Department for BioMedical Research (DBMR) (R.R.), University of Bern, Switzerland; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Science (N.B.), Moscow, Russia; Auckland University of Technology (N.B.), New Zealand; and Department of Surgery (R.D.C.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Christian W KellerFrom the Institute of Pharmacology (K.F.B., S.v.G.), University of Bern, Switzerland; Neurologic Clinic and Policlinic (J.O., L.K., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Switzerland; Department of Neurology with Institute of Translational Neurology (C.W.K., J.D.L.), University Hospital Münster, University of Münster, Germany; Laboratory of Neuroinflammation (C.W.K., B.P., J.D.L.), Institute of Experimental Immunology, University of Zurich, Switzerland; Department for BioMedical Research (DBMR) (R.R.), University of Bern, Switzerland; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Science (N.B.), Moscow, Russia; Auckland University of Technology (N.B.), New Zealand; and Department of Surgery (R.D.C.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0003-2276-0003
Benjamin PeschkeFrom the Institute of Pharmacology (K.F.B., S.v.G.), University of Bern, Switzerland; Neurologic Clinic and Policlinic (J.O., L.K., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Switzerland; Department of Neurology with Institute of Translational Neurology (C.W.K., J.D.L.), University Hospital Münster, University of Münster, Germany; Laboratory of Neuroinflammation (C.W.K., B.P., J.D.L.), Institute of Experimental Immunology, University of Zurich, Switzerland; Department for BioMedical Research (DBMR) (R.R.), University of Bern, Switzerland; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Science (N.B.), Moscow, Russia; Auckland University of Technology (N.B.), New Zealand; and Department of Surgery (R.D.C.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Robert RiebenFrom the Institute of Pharmacology (K.F.B., S.v.G.), University of Bern, Switzerland; Neurologic Clinic and Policlinic (J.O., L.K., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Switzerland; Department of Neurology with Institute of Translational Neurology (C.W.K., J.D.L.), University Hospital Münster, University of Münster, Germany; Laboratory of Neuroinflammation (C.W.K., B.P., J.D.L.), Institute of Experimental Immunology, University of Zurich, Switzerland; Department for BioMedical Research (DBMR) (R.R.), University of Bern, Switzerland; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Science (N.B.), Moscow, Russia; Auckland University of Technology (N.B.), New Zealand; and Department of Surgery (R.D.C.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Nicolai BovinFrom the Institute of Pharmacology (K.F.B., S.v.G.), University of Bern, Switzerland; Neurologic Clinic and Policlinic (J.O., L.K., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Switzerland; Department of Neurology with Institute of Translational Neurology (C.W.K., J.D.L.), University Hospital Münster, University of Münster, Germany; Laboratory of Neuroinflammation (C.W.K., B.P., J.D.L.), Institute of Experimental Immunology, University of Zurich, Switzerland; Department for BioMedical Research (DBMR) (R.R.), University of Bern, Switzerland; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Science (N.B.), Moscow, Russia; Auckland University of Technology (N.B.), New Zealand; and Department of Surgery (R.D.C.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Ludwig KapposFrom the Institute of Pharmacology (K.F.B., S.v.G.), University of Bern, Switzerland; Neurologic Clinic and Policlinic (J.O., L.K., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Switzerland; Department of Neurology with Institute of Translational Neurology (C.W.K., J.D.L.), University Hospital Münster, University of Münster, Germany; Laboratory of Neuroinflammation (C.W.K., B.P., J.D.L.), Institute of Experimental Immunology, University of Zurich, Switzerland; Department for BioMedical Research (DBMR) (R.R.), University of Bern, Switzerland; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Science (N.B.), Moscow, Russia; Auckland University of Technology (N.B.), New Zealand; and Department of Surgery (R.D.C.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Richard D CummingsFrom the Institute of Pharmacology (K.F.B., S.v.G.), University of Bern, Switzerland; Neurologic Clinic and Policlinic (J.O., L.K., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Switzerland; Department of Neurology with Institute of Translational Neurology (C.W.K., J.D.L.), University Hospital Münster, University of Münster, Germany; Laboratory of Neuroinflammation (C.W.K., B.P., J.D.L.), Institute of Experimental Immunology, University of Zurich, Switzerland; Department for BioMedical Research (DBMR) (R.R.), University of Bern, Switzerland; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Science (N.B.), Moscow, Russia; Auckland University of Technology (N.B.), New Zealand; and Department of Surgery (R.D.C.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Jens KuhleFrom the Institute of Pharmacology (K.F.B., S.v.G.), University of Bern, Switzerland; Neurologic Clinic and Policlinic (J.O., L.K., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Switzerland; Department of Neurology with Institute of Translational Neurology (C.W.K., J.D.L.), University Hospital Münster, University of Münster, Germany; Laboratory of Neuroinflammation (C.W.K., B.P., J.D.L.), Institute of Experimental Immunology, University of Zurich, Switzerland; Department for BioMedical Research (DBMR) (R.R.), University of Bern, Switzerland; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Science (N.B.), Moscow, Russia; Auckland University of Technology (N.B.), New Zealand; and Department of Surgery (R.D.C.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Stephan von GuntenFrom the Institute of Pharmacology (K.F.B., S.v.G.), University of Bern, Switzerland; Neurologic Clinic and Policlinic (J.O., L.K., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Switzerland; Department of Neurology with Institute of Translational Neurology (C.W.K., J.D.L.), University Hospital Münster, University of Münster, Germany; Laboratory of Neuroinflammation (C.W.K., B.P., J.D.L.), Institute of Experimental Immunology, University of Zurich, Switzerland; Department for BioMedical Research (DBMR) (R.R.), University of Bern, Switzerland; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Science (N.B.), Moscow, Russia; Auckland University of Technology (N.B.), New Zealand; and Department of Surgery (R.D.C.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-2753-8738
Jan D LünemannFrom the Institute of Pharmacology (K.F.B., S.v.G.), University of Bern, Switzerland; Neurologic Clinic and Policlinic (J.O., L.K., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Switzerland; Department of Neurology with Institute of Translational Neurology (C.W.K., J.D.L.), University Hospital Münster, University of Münster, Germany; Laboratory of Neuroinflammation (C.W.K., B.P., J.D.L.), Institute of Experimental Immunology, University of Zurich, Switzerland; Department for BioMedical Research (DBMR) (R.R.), University of Bern, Switzerland; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Science (N.B.), Moscow, Russia; Auckland University of Technology (N.B.), New Zealand; and Department of Surgery (R.D.C.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. jan.luenemann@ukmuenster.de.ORCID 0000-0002-3007-708X
University of Bern · CH
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the repertoire of glycan-specific immunoglobulin G (IgG) antibodies in treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS).
methodsA systems-level approach combined with glycan array technologies was used to determine specificities and binding reactivities of glycan-specific IgGs in treatment-naive patients with RRMS compared with patients with noninflammatory and other inflammatory neurologic diseases.
resultsWe identified a unique signature of glycan-binding IgG in MS with high reactivities to the dietary xenoglycan N-glycolylneuraminic acid (Neu5Gc) and the self-glycan N-acetylneuraminic acid (Neu5Ac). Increased reactivities of serum IgG toward Neu5Gc and Neu5Ac were additionally observed in an independent, treatment-naive cohort of patients with RRMS.
conclusionPatients with MS show increased IgG reactivities to structurally related xenogeneic and human neuraminic acids. The discovery of these glycan-specific epitopes as immune targets and potential biomarkers in MS merits further investigation.
Indexed as
AdultAutoantibodiesBiomarkersEpitopesFemaleHumansImmunoglobulin GMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingN-Acetylneuraminic AcidNeuraminic AcidsAutoantibodiesBiomarkersEpitopesImmunoglobulin GN-Acetylneuraminic AcidNeuraminic AcidsN-glycolylneuraminic acid
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.